Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven®) therapy in haemophilia a patients

Thrombosis Research

Volumn 126, Issue 2, 2010, Pages 144-149

  Viuff, Dorthe ^a   Andersen, Søren ^a   Sørensen, Brit B ^a   Lethagen, Stefan ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Haemophilia A; Monitoring; rFVIIa (NovoSeven); TEG; Thrombelastogram

Indexed keywords

HAEMATE; HEMOGLOBIN; KAOLIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT THROMBOPLASTIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ASSAY; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; FIBRINOLYSIS; HEMATOCRIT; HEMOPHILIA A; HEMOSTASIS; HUMAN; MALE; PATIENT MONITORING; PRIORITY JOURNAL; THROMBOCYTE; THROMBOELASTOGRAPHY; TREATMENT OUTCOME;

ADOLESCENT; COAGULANTS; DRUG MONITORING; FACTOR VIIA; HEMOPHILIA A; HUMANS; MALE; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; THROMBELASTOGRAPHY; YOUNG ADULT;

EID: 77955714195     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.05.008     Document Type: Article

References (23)

1. C. Negrier, Y. Dargaud, and J.C. Bordet Basic aspects of bypassing agents Haemophilia 12 Suppl 6 2006 48 52
2. H.R. Roberts, D.M. Monroe, and G.C. White The use of recombinant factor VIIa in the treatment of bleeding disorders Blood 104 2004 3858 3864
3. B. Sorensen, and J. Ingerslev Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography Haemophilia 11 Suppl 1 2005 1 6
4. S. Bassus, W. Wegert, M. Krause, C. Escuriola-Ettinghausen, A. Siegemund, and S. Petros Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A Platelets 17 2006 378 384
5. B. Sørensen, and J. Ingerslev Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa J Thromb Haemost 2 2004 102 110
6. G. Young, R. Blain, P. Nakagawa, and D.J. Nugent Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography Haemophilia 12 2006 598 604
7. Y. Dargaud, S. Beguin, A. Lienhart, D.R. Al, C. Trzeciak, and J.C. Bordet Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B Thromb Haemost 93 2005 475 480
8. H. Dehmel, S. Werwitzke, A. Trummer, A. Ganser, and A. Tiede Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia Haemophilia 14 2008 736 742
9. H. Dehmel, S. Werwitzke, A. Trummer, A. Ganser, and A. Tiede Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia Haemophilia 14 2008 736 742
10. B. Sørensen, P. Johansen, K. Christiansen, M. Woelke, and J. Ingerslev Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation J Thromb Haemost 1 2003 551 558
11. G. Young, L.S. Ebbesen, D. Viuff, P.J. Di, B.A. Konkle, and C. Negrier Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial Blood Coagul Fibrinolysis 19 2008 276 282
12. G. Young, R. Blain, P. Nakagawa, and D.J. Nugent Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography Haemophilia 12 2006 598 604
13. H.R. Roberts Choice of replacement therapy for hemophilia J Thromb Haemost 1 2003 595
14. K. Kavakli, M. Makris, B. Zulfikar, E. Erhardtsen, Z.S. Abrams, and G. Kenet Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial Thromb Haemost 95 2006 600 605
15. A. Chuansumrit, N. Sri-Udomporn, V. Srimuninnimit, and R. Juntarukha A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors Haemophilia : the official journal of the World Federation of Hemophilia 7 2001 532 534
16. H.A. Cooper, C.P. Jones, E. Campion, H.R. Roberts, and U. Hedner Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures Haemophilia 7 2001 517 522
17. G. Kenet, A. Lubetsky, S. Gitel, J. Luboshitz, D. Varon, and U. Martinowitz Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VII Blood Coagul Fibrinolysis 11 Suppl 1 2000 S35 S38
18. J. Astermark, S.M. Donfield, D.M. DiMichele, A. Gringeri, S.A. Gilbert, and J. Waters A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study Blood 109 2007 546 551
19. C. Negrier The concept of recombinant factor VIIa megadose for treating bleeding episodes in high-titer inhibitor patients with hemophilia: toward an expanding indication? J Thromb Haemost 1 2003 423 424
20. M. Hoffman, D.M. Monroe, and H.R. Roberts Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII Blood Coagul Fibrinolysis 9 Suppl 1 1998 S61 S65
21. M. Hoffman, D.M. Monroe, and H.R. Roberts Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia Blood 83 1994 38 42
22. M. Hoffman, and I.I.I. Monroe A cell-based model of hemostasis Thromb Haemost 85 2001 958 965
23. T. Lisman, L.O. Mosnier, T. Lambert, E.P. Mauser-Bunschoten, J.C. Meijers, and H.K. Nieuwenhuis Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A Blood 99 2002 175 179